Naproxen Warning Unjustified, Say FDA Experts
Report Linking Aleve to Heart Attacks Unnecessarily Scared Public
WebMD News Archive
Feb. 18, 2005 - A report last year that linked the pain killer naproxen to heart attacks unnecessarily scared the public, experts charged Friday.
FDA advisory panel members reviewing the safety of the arthritis drug Vioxx and similar drugs accused National Institutes of Health officials of acting irresponsibly when they stopped a study testing the drugs Naproxen is sold under many brand names, including Aleve and Naprosyn.
The NIH halted the trial, called ADAPT, after data suggested that naproxen raised the risk of heart attack and stroke in study patients.
An earlier study showed that Celebrex had similar risks.
NIH Director Elias A. Zerhouni, MD, released a statement saying that the trial was being stopped "as a precautionary measure to ensure the safety of the study's participants" and that the researchers made their decision based on the risk/benefit analysis specific to this trial.
But one ADAPT researcher told the panel Friday that naproxen's effect on heart risk was "barely significant" and that the study was not stopped because of safety concerns. Instead, officials halted the trial because of a concern that questions on the safety of and related drugs would make study participants reluctant to take their medications and damage the integrity of the study.
"There seemed little practical choice but to do so," said Constantine Lyketsos, MD, a Johns Hopkins University researcher who was part of the ADAPT study team. Some study patients had already begun to resist taking their drugs, and study directors became fearful that patients would "vote with their feet" and stop participating altogether.
"We feared further erosion" of the study, he said.
Lyketsos also said that study leaders faced an ethical dilemma of continuing with an Alzheimer's prevention study with no expected immediate benefit to patients, given possible safety concerns with Celebrex, Vioxx, and similar drugs, called Cox-2 inhibitors.
FDA experts harshly criticized the NIH's announcement, saying that it potentially scared millions of naproxen patients despite some pervious data suggesting that the drug may actually be safer for the heart than Cox-2 drugs.